Log In
Print this Print this


  Manage Alerts
Collapse Summary General Information
Company Numab AG
DescriptionBispecific antibody fragment targeting interleukin-23 (IL-23) receptor and CD3
Molecular Target Interleukin-23 (IL-23) ; CD3
Mechanism of ActionBispecific antibody
Therapeutic ModalityBiologic: Antibody

 Product Details
Disease CategoryStandard IndicationIndication DetailsPartnersMilestonesLatest Stage of DevelopmentRegulatory Designation
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today